SIRT5 and neoplasm: Thus, therapies that increase malonylations in tumor cells (via SIRT5 inhibition, MCD inhibition, or the delivery of cell-permeable malonyl-CoA analogs that specifically malonylate certain targets) are being explored as anticancer strategies.